Sorafenib Tosylate (Synonyms: Bay 43-9006 Tosylate)

Name: Sorafenib Tosylate
Brand: MedChemExpress
SKU: HY-10201A
Rating: 5.0 (204 reviews)

Cat. No.: HY-10201A Purity: 99.91%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Sorafenib Tosylate (Bay 43-9006 Tosylate) is a potent and orally active Raf inhibitor with IC₅₀s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. SorafenibTosylate is a multikinase inhibitor with IC₅₀s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib Tosylate induces autophagy and apoptosis. Sorafenib Tosylate has anti-tumor activity. Sorafenib Tosylate is a ferroptosis activator.

For research use only. We do not sell to patients.

Sorafenib Tosylate Chemical Structure

CAS No. : 475207-59-1

Size	Price	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 73	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 73	In-stock	Estimated Time of Arrival: December 31
Solid
100 mg	USD 66	In-stock	Estimated Time of Arrival: December 31
500 mg	USD 86	In-stock	Estimated Time of Arrival: December 31
1 g		Get quote
5 g		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 204 publication(s) in Google Scholar

Other Forms of Sorafenib Tosylate:

Sorafenib In-stock
Sorafenib Tosylate (Standard) Get quote

192 Publications Citing Use of MCE Sorafenib Tosylate

RT-PCR

Cell Viability Assay

Proliferation Assay

: Sorafenib Tosylate purchased from MedChemExpress. Usage Cited in: Discov Oncol. 2023 May 27;14(1):83. [Abstract]; Sorafenib (3 µM; 24 h) significantly inhibits the cell proliferation of HepG2 and Hep3B.

: Sorafenib Tosylate purchased from MedChemExpress. Usage Cited in: Discov Oncol. 2023 May 27;14(1):83. [Abstract]; Sorafenib (0.25, 0.5, 1, 2, 4, 6 µM; 24 h) significantly inhibits the cell viability of HepG2 and Hep3B.

: Sorafenib Tosylate purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2018 Apr 25;14(5):577-585. [Abstract]; Hep3B, HepG2 and Huh7 cells are treated with 5 μM Sorafenib. The expressing levels of JAK1, JAK2, STAT3, SHP1, SHP2, actin and phosphorylation levels of STAT3 are determined by western blot using the antibodies, respectively.

: Sorafenib Tosylate purchased from MedChemExpress. Usage Cited in: Oncol Rep. 2018 Sep;40(3):1525-1532. [Abstract]; SMMC-7721 and HepG2 cells are treated with 4 µM Sorafenib and 100 µM Berberine alone or in combination (4 µM Sorafenib+100 µM Berberine) for 72 h, and the expression levels of apoptosis-associated proteins are measured by western blot analysis.

: Sorafenib Tosylate purchased from MedChemExpress. Usage Cited in: Br J Cancer. 2017 Sep 26;117(7):974-983. [Abstract]; The effect of the AKT inhibitor MK2206 (10 μM) on the expression levels of phosphor-AKT, AKT, and STMN1 in TKI-pretreated NCI-H460 cells. β-actin is used as a loading control.

: Sorafenib Tosylate purchased from MedChemExpress. Usage Cited in: Am J Cancer Res. 2017 Dec 1;7(12):2503-2514. [Abstract]; VPA potentiates anti-tumor effects of Sorafenib tosylate in vivo. The expression of cleaved caspase9, cleaved caspase3, cleaved PARP from tumor tissue homogenates are analyzed by western blot.

: Sorafenib Tosylate purchased from MedChemExpress. Usage Cited in: J Pharmacol Exp Ther. 2017 Aug;362(2):219-229. [Abstract]; The combination of sorafenib and CAI induces apoptosis in NSCLC. Effect of 10 μM CAI and/or 5 μM Sorafenib on the expression of cleaved PARP and cleaved caspase-. Protein levels of cleaved PARP and cleaved caspase-3 from treated cell lysates are normalized against GAPDH levels.

: Sorafenib Tosylate purchased from MedChemExpress. Usage Cited in: Endocr J. 2017 Nov 29;64(11):1115-1123. [Abstract]; Effect of Sorafenib and Forskolin on expression of CDK4 and CDK regulatory proteins. Thyroid cancer cells are treated for 24 hours with 10 μM Sorafenib, 10 μM Forskolin, and combination therapy of 10 μM Sorafenib with 10 μM Forskolin. The expression of cyclin D1, CDK4, and phosphorylation of RB are examined by immunoblot analysis. β-actin is used as the control. The combination therapy suppresses expression of cyclin D1, and Forskolin monotherapy suppresses expression of cyclin D1 in TPC-1 and W

: Sorafenib Tosylate purchased from MedChemExpress. Usage Cited in: Endocr J. 2017 Nov 29;64(11):1115-1123. [Abstract]; Effect of Sorafenib on phosphorylation of ERK and AKT. Thyroid cancer cells are treated for 30 minutes with 10 μM Sorafenib, 10 μM Forskolin, and combination therapy of 10 μM Sorafenib with 10 μM Forskolin. The levels of ERK and AKT phosphorylation are examined by immunoblot analysis. β-actin is used as the control. Sorafenib suppresses phosphorylation of ERK, but not of AKT.

: Sorafenib Tosylate purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 May 2;8(18):29771-29784. [Abstract]; Sorafenib inhibits Pin1 biosynthesis and accumulation in Huh7 and HepG2 cells. Cells are treated with 5 or 10 μM Sorafenib for indicated times. Pin1 protein expression is determined by Western Blot.

: Sorafenib Tosylate purchased from MedChemExpress. Usage Cited in: Int J Clin Exp Pathol. 2015 Apr 1;8(4):3871-81. [Abstract]; The relationship between SOX9 and Raf/MEK/ERK signaling pathway. Co-treatment of si-SOX9-1 and Sorafenib (10uM, 15uM)/SU 11248 (2 uM, 3 uM) significantly decreases expression of MEK1 and its phosphorylated protein (p-MEK1/2, p-ERK1/2) as assayed by RT-PCR (with β-actin as internal control).

: Sorafenib Tosylate purchased from MedChemExpress. Usage Cited in: Int J Clin Exp Pathol. 2015 Apr 1;8(4):3871-81. [Abstract]; The relationship between SOX9 and Raf/MEK/ERK signaling pathway. Co-treatment of si-SOX9-1 and Sorafenib (10uM, 15uM)/SU 11248 (2 uM, 3 uM) significantly decreases expression of MEK1 and its phosphorylated protein (p-MEK1/2, p-ERK1/2) as assayed by Western blot (with GAPDH as internal control).

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Raf Isoform Specific Products:

View All Isoforms

BRaf c-Raf Raf

View All VEGFR Isoform Specific Products:

View All Isoforms

VEGFR1/Flt-1 VEGFR2/KDR/Flk-1 VEGFR3/Flt-4

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]

VEGFR3

20 nM (IC₅₀)

Braf

22 nM (IC₅₀)

Raf-1

6 nM (IC₅₀)

VEGFR2

90 nM (IC₅₀)

Braf^V599E

38 nM (IC₅₀)

PDGFRβ

57 nM (IC₅₀)

c-Kit

68 nM (IC₅₀)

Flt3

58 nM (IC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
Caco-2	CC₅₀	1.17 μM Compound: SORAFENIB	Toxicity against Caco-2 cells determined at 48 hours by intracellular ATP concentration using the CellTiter-Glo Luminescent Cell Viability Assay Toxicity against Caco-2 cells determined at 48 hours by intracellular ATP concentration using the CellTiter-Glo Luminescent Cell Viability Assay	10.21203/rs.3.rs-23951/v1
Caco-2	IC₅₀	1.55 μM Compound: SORAFENIB	Determination of IC50 values for inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells after 48 hours by high content imaging Determination of IC50 values for inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells after 48 hours by high content imaging	10.21203/rs.3.rs-23951/v1
CAKI-1	GI₅₀	3.2 μM Compound: NSC 747971	Antiproliferative activity against human CAKI-1 cells after 48 hrs by SRB assay Antiproliferative activity against human CAKI-1 cells after 48 hrs by SRB assay	[PMID: 22560627]
EKVX	GI₅₀	2.5 μM Compound: NSC 747971	Antiproliferative activity against human EKVX cells after 48 hrs by SRB assay Antiproliferative activity against human EKVX cells after 48 hrs by SRB assay	[PMID: 22560627]
HeLa	EC₅₀	> 10 μM Compound: Nexavar	Toxicity in human HeLa cells assessed as cell cycle arrest at G2M phase by flow cytometry based phenotypic drug discovery based assay Toxicity in human HeLa cells assessed as cell cycle arrest at G2M phase by flow cytometry based phenotypic drug discovery based assay	[PMID: 22409666]
Hep 3B2	IC₅₀	1.5 μM Compound: 6	Cytotoxicity against human Hep3B cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human Hep3B cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 30108693]
HepG2	IC₅₀	214.8 nM Compound: ST	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 33002846]
HT-29	GI₅₀	2.5 μM Compound: NSC 747971	Antiproliferative activity against human HT-29 cells after 48 hrs by SRB assay Antiproliferative activity against human HT-29 cells after 48 hrs by SRB assay	[PMID: 22560627]
Huh-7	IC₅₀	1.6 μM Compound: 6	Cytotoxicity against human HuH7 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human HuH7 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 30108693]
HUVEC	IC₅₀	1954 nM Compound: ST	Antiproliferative activity against human HUVEC assessed as reduction in cell viability incubated for 24 hrs by MTT assay Antiproliferative activity against human HUVEC assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 33002846]
Mahlavu	IC₅₀	0.7 μM Compound: 6	Cytotoxicity against human Mahlavu cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human Mahlavu cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 30108693]
MCF7	IC₅₀	1384 nM Compound: ST	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 33002846]
MCF7	GI₅₀	2.5 μM Compound: NSC 747971	Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 22560627]
MDA-MB-231	IC₅₀	349.3 nM Compound: ST	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 33002846]
MDA-MB-435	GI₅₀	2 μM Compound: NSC 747971	Antiproliferative activity against human MDA-MB-435 cells after 48 hrs by SRB assay Antiproliferative activity against human MDA-MB-435 cells after 48 hrs by SRB assay	[PMID: 22560627]
OVCAR-3	GI₅₀	3.2 μM Compound: NSC 747971	Antiproliferative activity against human OVCAR3 cells after 48 hrs by SRB assay Antiproliferative activity against human OVCAR3 cells after 48 hrs by SRB assay	[PMID: 22560627]
Sf9	IC₅₀	12.5 nM Compound: Nexavar	Inhibition of GST-tagged recombinant human VEGFR2 expressed in Sf9 cells by radiometric assay Inhibition of GST-tagged recombinant human VEGFR2 expressed in Sf9 cells by radiometric assay	[PMID: 24368209]
SNB-19	GI₅₀	3.2 μM Compound: NSC 747971	Antiproliferative activity against human SNB19 cells after 48 hrs by SRB assay Antiproliferative activity against human SNB19 cells after 48 hrs by SRB assay	[PMID: 22560627]
SW-620	GI₅₀	3.2 μM Compound: NSC 747971	Antiproliferative activity against human SW620 cells after 48 hrs by SRB assay Antiproliferative activity against human SW620 cells after 48 hrs by SRB assay	[PMID: 22560627]
TK-10	GI₅₀	5 μM Compound: NSC 747971	Antiproliferative activity against human TK10 cells after 48 hrs by SRB assay Antiproliferative activity against human TK10 cells after 48 hrs by SRB assay	[PMID: 22560627]
UACC-257	GI₅₀	2 μM Compound: NSC 747971	Antiproliferative activity against human UACC257 cells after 48 hrs by SRB assay Antiproliferative activity against human UACC257 cells after 48 hrs by SRB assay	[PMID: 22560627]

In Vitro

Sorafenib Tosylate also inhibits BRAF^wt (IC₅₀=22 nM), BRAF^V599E (IC₅₀=38 nM), VEGFR-2 (IC₅₀=90 nM), VEGFR-3 (IC₅₀=20 nM), PDGFR-β (IC₅₀=57 nM), c-KIT (IC₅₀=68 nM), and Flt3 (IC₅₀=58 nM) in biochemical assays^[1].
Sorafenib Tosylate-induced phosphorylation of c-Met, p70S6K and 4EBP1 is significantly reduced when 10-0505 cells are co-treated with anti-human anti-HGF antibody, suggesting that treatment with Sorafenib Tosylate leads to increased HGF secretion and activation of c-Met and mTOR targets^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Sorafenib Tosylate (10, 30, 50 and 100 mg/kg, orally) treatment inhibits the tumor growth of 06-0606 and 10-0505 xenografts in a dose-dependent manner (P<0.01). The growth rate of 06-0606 and 10-0505 xenografts is also significantly reduced by Sorafenib. The weights of 06-0606 tumors in mice that are treated with Sorafenib 50 mg/kg and 100 mg/kg are approximately 13% and 5% of the controls, respectively. 50 mg dose of Sorafenib significantly inhibits tumor growth in mice with lines 5-1318, 26-1004 and 10-0505 (P<0.01). For 50 mg dose, the T/C ratio, where T and C are the median weight (mg) of Sorafenib- and vehicle-treated tumors at the end of the treatment, respectively, for 06-0606, 26-1004, 5-1318, and 10-0505 xenografts is 0.13, 0.10, 0.12 and 0.49, respectively^[2]. The survival rate is 73.3 % in Diethyl nitrosamine (DENA) group and 83.3 % in Sorafenib group compared to 100 % in the normal control group. DENA group shows a significant increase in liver index (1.51-fold increase, p<0.05) compared to normal control group, while treatment with Sorafenib shows significant decrease (p<0.05) in liver index when compared to DENA group. The liver index in Sorafenib group significantly decreases to lower than its value in the normal control^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

637.03

Formula

C₂₈H₂₄ClF₃N₄O₆S

CAS No.

475207-59-1

Appearance

Solid

Color

White to off-white

SMILES

O=S(C1=CC=C(C=C1)C)(O)=O.O=C(NC2=CC=C(C(C(F)(F)F)=C2)Cl)NC3=CC=C(OC4=CC(C(NC)=O)=NC=C4)C=C3

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

*In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : ≥ 31 mg/mL (48.66 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.5698 mL	7.8489 mL	15.6978 mL
5 mM	0.3140 mL	1.5698 mL	3.1396 mL
10 mM	0.1570 mL	0.7849 mL	1.5698 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.08 mg/mL (3.27 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (3.27 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (3.27 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 20% HP-β-CD in Saline
Solubility: 5 mg/mL (7.85 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.91%

Select Batch:

Data Sheet (280 KB) SDS (563 KB)

COA (243 KB) LCMS (99 KB)

Handling Instructions (2659 KB)

References

[1]. Wilhelm SM, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004 Oct 1;64(19):7099-109. [Content Brief]

[2]. Huynh H, et al. Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Cell Mol Med. 2009 Aug;13(8B):2673-83. [Content Brief]

[3]. El-Ashmawy NE, et al. Sorafenib effect on liver neoplastic changes in rats: more than a kinase inhibitor. Clin Exp Med. 2016 Apr 16. [Content Brief]

[4]. Zhu W, et al. Combination of sorafenib and Valproic acid synergistically induces cell apoptosis and inhibits hepatocellular carcinoma growth via down-regulating Notch3 and pAkt. Am J Cancer Res. 2017 Dec 1;7(12):2503-2514. [Content Brief]

Kinase Assay ^[1]	To test compound inhibition against various RAF kinase isoforms, Sorafenib is added to a mixture of Raf-1 (80 ng), wt BRAF, or V599E BRAF (80 ng) with MEK-1 (1 μg) in assay buffer [20 mM Tris (pH 8.2), 100 mM NaCl, 5 mM MgCl₂, and 0.15% β-mercaptoethanol] at a final concentration of 1% DMSO. The RAF kinase assay (final volume of 50 μL) is initiated by adding 25 μL of 10 μM γ-[³³P]ATP (400 Ci/mol) and incubated at 32°C for 25 minutes. Phosphorylated MEK-1 is harvested by filtration onto a phosphocellulose mat, and 1% phosphoric acid is used to wash away unbound radioactivity. After drying by microwave heating, a β-plate counter is used to quantify filter-bound radioactivity^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Assay ^[2]	The 10-0505, 06-0606, and 26-1004 tumors are finely minced and washed three times with modified Eagle medium (MEM). Cells are harvested by centrifuging at 800× g for 10 min. Cells are treated with 3 or 6 μM of Sorafenib in serum free MEM in the presence or absence of 5 μg/mL anti-human hepatocyte growth factor (HGF) antibody for 48 hrs. A total of 2 mL of conditioned medium from vehicle- or Sorafenib-treated (without anti-human antibody) is collected and concentrated using a VIVASPIN 20 and secreted HGF in conditioned medium is determined by western blotting^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[2]^[3]	Mice^[2] For dose-response experiment, mice bearing the 06-0606 and 10-0505 xenografts are given four doses of Sorafenib (10, 30, 50 and 100 mg/kg daily) orally for 12 days. Each treatment group comprised of five mice. To investigate the antitumor effects of Sorafenib, mice bearing tumors are orally administered 50 mg/kg Sorafenib daily for 12 days. Each treatment group is comprised of 14 animals and each experiment is repeated at least twice. Treatment started on day 7 after tumor implantation. By this time, the HCC xenografts reached the size of approximately 100 mm³. To study the effects of Rapamycin plus Sorafenib on the growth of 10-0505 xenograft, mice bearing tumors (14 per group) are orally administered either 200 μL of vehicle, or 50 mg/kg of Sorafenib, or 1 mg/kg of Rapamycin, or Rapamycin plus Sorafenib daily for indicated days. Tumor growth is monitored at least twice weekly by Vernier caliper measurement of the length and width of tumor. Tumor volume is calculated as follows: [length×width²×π/6]. At the end of the study, the mice are killed with body and tumor weights being recorded, and the tumors harvested for analysis. Rats^[3] In the study, 100- to 120-g male albino rats are utilized. After acclimatization period, rats are weighed and randomly divided into three groups: Group 1 (normal control group; n=10) is given the vehicle daily for 8 weeks. Group 2 (DENA group; n=15) receive i.p. single dose of 200 mg/kg DENA. Group 3 (Sorafenib group; n=12) is given Sorafenib orally at a dose of 10 mg/kg daily for 2 weeks, 6 weeks after DENA i.p. injection. At the end of the experiment (8 weeks), rats are weighed, anesthetized by ether, and killed, and their livers are dissected. Fresh liver is washed twice with ice-cold saline, dried on clean paper towel, and weighed. Liver index is calculated as liver weight (g)/final body weight (g)×100. The liver is divided into five portions: one portion is preserved in 10 % formalin for histopathological examination and the other portions are immediately frozen in liquid nitrogen and stored at −80°C. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Wilhelm SM, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004 Oct 1;64(19):7099-109. [Content Brief] [2]. Huynh H, et al. Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Cell Mol Med. 2009 Aug;13(8B):2673-83. [Content Brief] [3]. El-Ashmawy NE, et al. Sorafenib effect on liver neoplastic changes in rats: more than a kinase inhibitor. Clin Exp Med. 2016 Apr 16. [Content Brief] [4]. Zhu W, et al. Combination of sorafenib and Valproic acid synergistically induces cell apoptosis and inhibits hepatocellular carcinoma growth via down-regulating Notch3 and pAkt. Am J Cancer Res. 2017 Dec 1;7(12):2503-2514. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.5698 mL	7.8489 mL	15.6978 mL	39.2446 mL
	5 mM	0.3140 mL	1.5698 mL	3.1396 mL	7.8489 mL
	10 mM	0.1570 mL	0.7849 mL	1.5698 mL	3.9245 mL
	15 mM	0.1047 mL	0.5233 mL	1.0465 mL	2.6163 mL
	20 mM	0.0785 mL	0.3924 mL	0.7849 mL	1.9622 mL
	25 mM	0.0628 mL	0.3140 mL	0.6279 mL	1.5698 mL
	30 mM	0.0523 mL	0.2616 mL	0.5233 mL	1.3082 mL
	40 mM	0.0392 mL	0.1962 mL	0.3924 mL	0.9811 mL

Sorafenib Tosylate Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Sorafenib475207-59-1Bay 43-9006RafVEGFRFLT3AutophagyFerroptosisApoptosisRaf kinasesVascular endothelial growth factor receptorCluster of differentiation antigen 135CD135Fms like tyrosine kinase 3Inhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Salutation
Applicant Name *			Email Address *
Phone Number *			Organization Name *
Department *			Requested quantity *
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Sorafenib Tosylate (Synonyms: Bay 43-9006 Tosylate)

Customer Review

Other Forms of Sorafenib Tosylate:

Sorafenib Tosylate Related Antibodies

192 Publications Citing Use of MCE Sorafenib Tosylate

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Raf Isoform Specific Products:

View All VEGFR Isoform Specific Products:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Sorafenib Tosylate Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Sorafenib Tosylate Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report